

# **Novel Tools and Approaches Program**

David M. Crizer, Ph.D.

Division of the NTP

National Institute of Environmental Health Sciences

NTP Board of Scientific Counselors Meeting June 8, 2021





# **NTA Program Members**

### **Members from 5 DNTP branches**

### Liaison



Alex Merrick MTB



lan Chen MTB



David Crizer MTB



Rachel Frawley STB



Georgia Roberts OPO



Greg Travlos CMPB



Kristine Witt PTB

#### Ex Officio



Warren Casey PTB



Vickie Walker IHAB



Rick Paules PTB




## The Novel Tools and Approaches (NTA) Program

## What is the NTA Program?

The NTA Program is distinguished from the other programs that have been introduced previously

- NTA is not focused on a specific type of disease or exposure
- NTA is 1 of 2 programs charged with providing special capabilities to DNTP






# **The NTA Program**

## What is the NTA Program?


NTA is tasked with identifying new and novel testing approaches that may improve DNTP science by


- Increasing testing throughput
- Increasing speed of data acquisition from years to weeks
- Increasing data accuracy and precision
- Providing more in-depth analyses: molecular mode of action (MoA) and benchmark dose (BMD)
- Enhancing human relevance of DNTP studies






### **To Meet Public Health Needs and Expectations:**








## **Mission Alignment and Pipeline Engagement**





## **Mission Alignment and Pipeline Engagement**








Rapid, predictive, human-relevant data

• More efficient, innovative methods

 Reduce/refine animal use with focus on in vitro models










Rapid, predictive, human-relevant data

More efficient, innovative methods

 Reduce/refine animal use with focus on in vitro models









### **Rationale for NTA**

Rapid, predictive, human-relevant data


More efficient, innovative methods

 Reduce/refine animal use with focus on in vitro models




DNTP is positioned to lead

DNTP's history of developing innovative methodologies



- Resources
- Broad scientific expertise
- International collaborations







### **Public Health Context**

### Addressing the need for human relevant, actionable data

Risk

Exposure

In vitro assays Building Confidence in New Approaches


Human

Hazard

**Evaluate reliability** and relevance Rapid and Reliable Address **Uncertainties** Hazard Determination

BMD and MoA Data





- Translate observations to human exposure
- Data for in silico modeling/read-across
- Guide further studies in more complex systems or *in vivo* models



## **Current Portfolio of 28 Projects**

## **Balancing Risk and Reward**

Bioassays and Biological Systems

**Novel Technologies** 

Animal model substitutes

Small, short-term studies

Validated systems

Explore new models

Generating data for predictive modeling

Evaluate potential applications

Well-developed

Proof of principle and feasibility

Directly applicable to DNTP needs


Nascent technologies

Await characterization

Await validation





## **Current Portfolio of 28 Projects**






## **HepaRG Spheroid Model**







Ramaiahgari et al. Toxicol. Sci. 2017, 159, 124-136.

Ramaiahgari et al. *Toxicol. Sci.* **2019**, 169, 553-566.



### **Current Stakeholders**

- Regulatory Agencies
- International advisory committees
- Academic laboratories
- Government research centers
- Research specialty communities
- Primary end user of NTAs







UNITED STATES





European Food Safety Authority























National Center

















# **Objectives of the NTA Program**


- Identify and apply promising new technologies and approaches that enhance the efficiency and translational relevance of DNTP hazard assessments
  - Duplex sequencing for mutation analysis applicability to early-stage carcinogenesis



 High throughput Cystatin C measurements for monitoring kidney function in rodent tests



 5-day animal studies to capture signature transcriptomics changes following chemical exposure






# **Objectives of the NTA Program**


- 1. Identify and apply promising new technologies and approaches that enhance the efficiency and translational relevance of DNTP hazard assessments
- 2. Ensure that novel capability development is aligned to contemporary problems that DNTP is attempting to solve

### Cardiovascular diseases




3D iPSC cardiomyocytes

### Occupational exposures



Air-liquid interface (ALI) lung models

# Developmental neurotoxicology



Embryoid bodies

### Carcinogenesis



ddPCR



# **Objectives of the NTA Program**


- 1. Identify and apply promising new technologies and approaches that enhance the efficiency and translational relevance of DNTP hazard assessments
- 2. Ensure that novel capability development is aligned to contemporary problems that DNTP is attempting to solve
- Increase confidence in and adoption of NTAs, and foster development when need exists



## **Future NTA Development Areas**


### **Spheroids and Organoids**


**Neural Spheroids** 






Kidney organoids





High dimensional data streams

Tox21 Projects



3D Liver Models


High-throughput toxicity

Genotoxicity screening




 High-throughput screening
 Complex projects utilizing cutting-edge technologies

Microphysiological systems





## **Embryoid Bodies (EBs) for High-throughput Teratogen Screening**





# **Capability Development**

## Capability realization for 8 current projects

DNTP
Toxicology
Research
Regulatory
Acceptance
International
Regulatory
Acceptance

#### **Near Term**

**Available Now** 

- 5 day + TempOSeq
- 3D Liver Models
- In vitro skin sensitization

### **Medium Term**

1 - 2 years

- Ultra high throughput + S9
- Air-liquid interface
- Lung-on-a-chip

### **Longer Term**

3 - 5 years

- Metabolomics
- Embryoid bodies




Systems Toxicology Branch (STB)

Cardiovascular Program (CV)

Office of Program Operations (OPO)

Occupational and Inhalation Exposures Program (OIE)

Predictive Toxicology Branch (PTB)



Comparative and Molecular Pathogenesis Branch (CMPB)


Combined Exposures and Mixtures Program (CEM)


Emerging Contaminants and Issues of Concern Program (ECIC)

Mechanistic Toxicology Branch MTB)

Developmental Neurotoxicology Program (DNT)









Embryoid bodies






Air-liquid interface (ALI) lung models








5-day studies in rats





U.S. FOOD & DRUG

ADMINISTRATION



How would the BSC suggest the NTA go about identifying promising new technologies that appear to have direct application(s) to DNTP areas of investigation?



# **Thank You!**





## **NTA-PMT Members**

### **Members from 5 DNTP branches**

#### Liaison



Alex Merrick MTB



lan Chen MTB



David Crizer MTB



Rachel Frawley STB



Georgia Roberts OPO



Greg Travlos CMPB



Kristine Witt PTB